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Carcinomas are comprised of transformed epithelial cells that are
supported in their growth by a dedicated neovasculature. How the
genetic milieu of the epithelial compartment inﬂuences tumor
angiogenesis is largely unexplored. Drugs targeted to mutant
cancer genes may act not only on tumor cells but also, directly or
indirectly, on the surrounding stroma. We investigated the role of
the BRAFV600E oncogene in tumor/vessel crosstalk and analyzed
the effect of the BRAF inhibitor PLX4720 on tumor angiogenesis.
Knock-in of the BRAFV600E allele into the genome of human epithe-
lial cells triggered their angiogenic response. In cancer cells harbor-
ing oncogenic BRAF, the inhibitor PLX4720 switches off the ERK
pathway and inhibits the expression of proangiogenic molecules.
In tumor xenografts harboring the BRAFV600E, PLX4720 extensively
modiﬁes the vascular network causing abrogation of hypoxia.
Overall, our results provide a functional link between oncogenic
BRAF and angiogenesis. Furthermore, they indicate how the tumor
vasculature can be “indirectly” besieged through targeting of a
genetic lesion to which the cancer cells are addicted.
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Angiogenesis is a pivotal process for the growth, maintenance,and spread of the majority of solid tumors. In the early steps
of carcinogenesis, tumor cells require oxygen and nutrients,
which are supplied by newly formed vessels. During later phases
of cancer progression, blood vessels provide one of the most
important routes for tumor escape and metastasization (1, 2).
Notably, the structure of the vascular network dramatically alters
tumor features. Tumor vessels are disorganized, with perfusion
defects resulting in metabolic changes, hypoxia, and increase in
interstitial pressure (3). At the clinical level, these features are
associated with a more aggressive phenotype and a reduction of
drug delivery to the tumor mass (4, 5).
The angiogenic process is triggered and controlled by the
cancer cells, which carry genetic lesions that are causally associ-
ated with the neoplastic process. Understanding how individual
genetic lesions in oncogenes and tumor suppressor genes affect
directly or indirectly the angiogenic process is a fundamental
question that has been largely unexplored. It has been suggested
that alterations in oncogenes involved in the intracellular MAPK
signaling cascade play a central role in regulating tumor angio-
genesis (6). For example, KRAS activating mutations are thought
to sustain the chaotic tumor vasculature by up-regulating the
transcription of angiogenic inducers, including VEGF-A and IL-8
(7–9). BRAF binds to and is the main downstream effector of
KRAS. Whether and to what extent genetic alterations affect
BRAF-regulated angiogenesis is presently unclear. The most
common BRAF mutation is a valine-to-glutamate transition
(V600E), which results in constitutive activation of the kinase
activity. BRAFV600E is causally involved in the onset and pro-
gression of several cancers, including melanoma, papillary thy-
roid, colorectal, and ovarian tumors (10–12), and is often asso-
ciated with a particularly poor prognosis (13–17).
In addition to activation of aberrant cell proliferation,
BRAFV600E modulates tumor–stroma interaction and supports
cancer invasiveness by inﬂuencing the expression of metallo-
proteinases and cytokines (IL-6 and IL-10) involved in tumor-
immune escape (18, 19). Furthermore, BRAFV600E affects tumor
environment by enhancing the expression of HIF1α (20–22),
VEGF-A and IL-8 (23–25) and inhibiting the angiogenic blocker
thrombospondin 1 (26).
Speciﬁc and selective BRAF kinase inhibitors, such as
PLX4032/PLX4720, have recently shown remarkable clinical
success in patients with melanoma carrying the BRAFV600E mu-
tation (27–29).
Considering the putative role of mutant BRAF in modulating
cancer cell function and microenvironment, we hypothesized
that the efﬁcacy of PLX4720 could result from targeting the
epithelial and the stromal tumor compartments. In this work,
we assessed the contribution of BRAFV600E oncogene in pro-
moting angiogenesis, and investigated whether the BRAF in-
hibitor PLX4720 affects tumor angiogenesis and hypoxia.
Results
BRAFV600E Drives Angiogenesis in Chicken Chorioallantoic Membrane.
To study the speciﬁc inﬂuence of BRAFV600E on angiogenesis,
we used an isogenic model in which BRAFV600E was knocked-in
through homologous recombination into the genome of the
nontumorigenic human mammary epithelial cell line (hTERT-
HME1) (30). As a result, the mutant allele is expressed under its
endogenous promoter at levels comparable to wild type (WT)
thus overcoming the experimental drawbacks associated with
plasmid-driven ectopic overexpression.
Author contributions: A. Bottos, F.D.N., F.B., and A. Bardelli designed research; A. Bottos,
M.M., F.D.N., V.C., and F.M. performed research; A.M. and G.A. contributed new reagents/
analytic tools; A. Bottos, M.M., F.D.N., V.C., F.M., F.B., and A. Bardelli analyzed data; and
A. Bottos, F.D.N., F.B., and A. Bardelli wrote the paper.
Conﬂict of interest statement: A. Bardelli owns stock in, and has received consultancy fees
from, Horizon Discovery.
*This Direct Submission article had a prearranged editor.
1A. Bottos and M.M. contributed equally to this work.
2Present address: Friedrich Miescher Institute for Biomedical Research, CH-4058 Basel,
Switzerland.
3Present address: Department of Genetics, Biology and Biochemistry, Molecular Biotech-
nology Center, 10100 Turin, Italy.
4F.B. and A. Bardelli contributed equally to this work.
5To whom correspondence may be addressed. E-mail: federico.bussolino@ircc.it or alberto.
bardelli@ircc.it.
See Author Summary on page 1836.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1105026109/-/DCSupplemental.
www.pnas.org/cgi/doi/10.1073/pnas.1105026109 PNAS | February 7, 2012 | vol. 109 | no. 6 | E353–E359
M
ED
IC
A
L
SC
IE
N
CE
S
PN
A
S
PL
U
S
We used the chicken chorioallantoic membrane (CAM) assay
to assess whether BRAFV600E could modulate angiogenesis.
Compared with WT, BRAFV600E cells growing on CAM led to
a disorganized vasculature with several hemorrhagic areas as
measured by an arbitrary “angiogenic index” (Fig. 1 A, a and b,
and B). The quantiﬁcation of chicken endothelium within the
epithelial plugs revealed that BRAFV600E increased the re-
cruitment of endothelial cells (ECs) (Fig. 1 A, c–f, and C).
We next compared the transcriptional proﬁle of genes in-
volved in angiogenesis and inﬂammation between BRAFV600E
and parental hTERT-HME1 cells. To avoid clonal variability,
two independent BRAFV600E KI clones were evaluated. The
transcription analysis was performed in standard culture con-
ditions (on plastic) and on CAM. This comprehensive approach
revealed that oncogenic BRAFV600E enhanced the expression of
several proangiogenic and proinﬂammatory molecules, including
VEGF-A and C, TGF-α, and chemokines, such as CXCL1-2–3,
IL1β, and IL8 (Fig. S1 shows a list of differentially expressed
genes). Importantly, results from cells plated on CAM mirrored
those obtained in vitro, indicating that the chicken embryo mi-
croenvironment does not inﬂuence the transcriptional landscape
of the xenografted cells.
The ﬁnding that oncogenic BRAFV600E triggers up-regulation
of factors known to modulate angiogenesis led us to hypothesize
that the occurrence of this mutation in epithelial cells might
affect the endothelium. Among the factors that were pinpointed
by the transcriptional proﬁle, we focused on VEGF-A because
this molecule is a well known master switch of the angiogenic
program. BRAFV600E KI cells released higher amounts of
VEGF-A in the supernatant that enhanced EC migration com-
pared with the WT counterpart (Fig. 1 D and E). The chemo-
tactic effect of oncogenic BRAF on the ECs was abrogated by an
anti-VEGF blocking antibody, but not by an unrelated Ig (Fig.
1E). This observation supports the pivotal role of VEGF-A in
BRAFV600E -driven angiogenesis.
PLX4720 Exerts Cytostatic and Antiangiogenic Activities in Tumor
Harboring BRAFV600E.We next assessed whether the results obtained
by using the non-transformed isogenic cells might hold true in
cancer cells carrying the BRAFV600E allele. Cell lines of colorectal
cancer (COLO205) and melanoma (SK-MEL-28) origin were se-
lected because these tumor types frequently harbor mutations in
the BRAF gene (10). As expected, in vitro treatment with the
speciﬁc BRAFV600E inhibitor PLX4720 resulted in cell growth
inhibition and ERK inactivation in both cell lines, whereas AKT
phosphorylation was not affected (Fig. 2 A and B). Colorectal
cancer cells carrying WT BRAF (DiFi) were used as control and
proved insensitive to PLX4720 treatment (Fig. 2 A and B).
We next measured the effect of PLX4720 in vivo by growing
COLO205 and SK-MEL-28 subcutaneously in immunocompro-
mised mice. PLX4720 induced a prolonged cytostatic effect in
both xenograft models (Fig. 2 C and D, a and b). Importantly,
PLX4720-treated tumors did not show evident shrinkage and,
despite an initial regression in SK-MEL-28, at the end of the
experiments, tumor size was stabilized but not reduced. This was
further supported by the analysis of proliferation and apoptosis
assessed through Ki-67 staining and activation of caspase 3, re-
spectively. We found that PLX4720 markedly inhibited tumor
cell proliferation, whereas it was ineffective in inducing apoptosis
(Fig. 2 D, c–f, E, and F).
We then investigated the impact of PLX4720 on tumor an-
giogenesis in vivo. As differences in the tumor vasculature might
be inﬂuenced by cell proliferation and/or tumor size, we in-
troduced a third control group that involved samples obtained
when treatment was started. These samples (hereafter referred
to as “start point”) were carefully chosen to have approximately
the same volume of PLX4720-treated tumors. The comparative
analysis of the three groups allowed us to investigate the effect of
PLX4720 on tumor vasculature. As shown in Fig. 3A, PLX4720
induced profound changes in vascular architecture in COLO205
and SK-MEL-28 tumors. In the absence of treatment, the vas-
cularized area in COLO205 tumors did not change throughout
the experiment. Conversely, the area occupied by vessels in-
creased in PLX4720-treated samples compared with the vehicle
and start-point samples (Fig. 3B). This phenotype is likely the
consequence of morphological changes in vascular structure.
Fig. 1. KI of the BRAFV600E allele in hTERT-HME1 cells enhances angio-
genesis in CAM assay and increases VEGF-mediated migration of ECs. (A)
Representative images of hTERT-HME1 cells plated on the CAM (a and b).
(Scale bar: 1 mm.) Immunoﬂuorescence analysis of hTERT-HME1 cells plated
on the CAM. Human epithelial cells were stained with the HLA marker
(green) whereas blood vessels were labeled with the vWF, which is speciﬁc
for ECs (red) (c–f). Arrows indicate blood vessels. (Scale bar: 100 μm.) (B)
Qualitative assessment of angiogenesis (angiogenic index) in the CAM assay
(Materials and Methods). Bars represent the number of CAM samples that
exhibit low, medium, or high angiogenesis in parental or BRAFV600E mutant
cells. Measurements were performed by two observers in blinded fashion.
(C) Quantitative analysis of vWF intensity ﬂuorescence mean in hTERT-HME1
plugs. Data are expressed as fold change mean ± SEM (§P < 0.05, Student t
test; WT hTERT-HME1, n = 6; BRAFV600E KI hTERT-HME1, n = 9 samples). (D)
Quantiﬁcation of secreted VEGF-A in hTERT-HME1 cells by ELISA. Data are
expressed as mean ± SD of a technical replicate and are representative of
three independent experiments. (E) Migration of human ECs is enhanced by the
supernatant of hTERT-HME1 BRAFV600E KI cells compared with the WT coun-
terpart. Two different clones of BRAFV600E KI were analyzed (KI-A and KI-B).
SF, serum freemedium. VEGF blocking antibody (VEGF-Ab), but not unrelated
Ig, abolished BRAFV600E -induced cell migration. Bars represent the mean ±
SEM of the number of migrated cells of three samples (§P < 0.05, Student
t test). The representative of three independent experiments is shown.
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Indeed, blood vessels were enlarged and chaotic in control
tumors and thinner with an organized architecture in PLX4720-
treated samples (Fig. 3A, a–c). The average blood vessel di-
ameter decreased from 33 μm or 31 μm in start point and vehicle
groups, respectively, to 19 μm in treated samples (Fig. 3C).
Surprisingly, despite these evident morphological differences, the
blood vessel coverage by pericytes was unaffected by PLX4720
treatment (Fig. S2).
In SK-MEL-28 xenografts, the vascularized area increased in
vehicle-treated tumors whereas PLX4720 reduced the area oc-
cupied by vessels (Fig. 3B). Similar to what was observed in
COLO205, PLX4720 treatment of SK-MEL-28 tumors increased
the vascular surface area compared with start-point tumor. Fur-
thermore, the morphology of the vascular network in SK-MEL-28
was markedly modiﬁed and the blood vessel average diameter
was reduced from 14 μm compared with 23 μm and 22 μm in
start-point and vehicle groups, respectively (Fig. 3 A, d–f, and C).
PLX4720 Abrogates Hypoxia in BRAFV600E Tumors. The aberrant
morphology of blood vessels was strongly suggestive of altered
functionality of the microvasculature. We conﬁrmed this hy-
pothesis by the analysis of tumor perfusion before and after
PLX4720 treatment of COLO205 tumors. Tissue perfusion by
blood vessels was strongly increased in PLX4720-treated tumors
compared with vehicle or start-point groups, indicating an im-
proved functionality of microvasculature (Fig. 3D). Blood per-
fusion correlates with improved tissue oxygenation, which causes
deep changes in the overall features of tumor parenchyma (3).
We therefore studied the effect of PLX4720 on intratumoral
hypoxia in COLO205 and SK-MEL-28 xenografts and found that
PLX4720 prominently abolished hypoxia in treated tumors
compared with vehicle or start-point tumors (Fig. 4 A, a–c and g–
i, and B). Moreover, analysis of tumor tissues revealed that the
modiﬁcation of vascular structure by PLX4720 was linked to
reduced necrotic area in COLO205 and SK-MEL-28 xenografts
(Fig. 4 A d–f and j–l, and C). These results indicate that the effect
on hypoxia is independent from tumor growth and has implica-
tions for the therapeutic activity of PLX4720.
Importantly, targeting of angiogenesis by BRAF inhibition
showed signiﬁcant differences with respect to classical “VEGF
directed” antiangiogenic therapy. Treatment of COLO205 tumors
with the VEGF-blocking antibody bevacizumab resulted in sta-
bilization of tumor growth and strongly reduced microvascular
density (Fig. 5 A, B, g and h, and C). Concomitantly, tissue per-
fusion was impaired, and this led to persistent hypoxia and ne-
crosis (Fig. 5 B and D–F). The comparison between the two
Fig. 2. PLX4720 inhibits proliferation and turns off MAPK signaling in tumor cells carrying BRAFV600E. (A) Proliferation of COLO205 and SK-MEL-28, harboring
BRAFV600E, and BRAF WT DiFi cells, was assessed with increased PLX4720 concentration. Data are expressed as percentage of viability compared with vehicle
by the ATP assay. Mean ± SD of two independent experiments performed in quadruplicate is shown. (B) Biochemical analysis of phospho-ERK and phospho-
AKT (Ser473 and Thr308) in COLO205, SK-MEL-28, and DiFi cells. Protein loading was normalized by vinculin. Starved cells were stimulated for 30 min with
2.5% FBS plus 1 μM PLX4720 or vehicle. (C) Tumor growth curve of COLO205 and SK-MEL-28 xenografts. COLO205 and SK-MEL-28 xenografts were treated
with PLX4720 60 mg/kg or vehicle for 2 wk after tumor volume reached an average of 150 to 200 mm3. Arrows indicate the time point at which treatment was
started. Data are presented as mean tumor volume ± SEM. (D) Representative images of COLO205 tumors (a and b). (Scale bar: 4 mm.) Representative images
of Ki-67 staining in COLO205 (c and d) and SK-MEL-28 (e and f) xenografts. (Scale bar: 100 μm.) (E) Quantiﬁcation of proliferating cells by Ki-67 staining in
COLO205 and SK-MEL-28 xenografts. Bars show the mean of positive cells per 10× ﬁeld ± SD (§P < 0.0001, Student t test). For COLO205, vehicle, n = 4 mice;
PLX4720, n = 6 mice; for SK-MEL-28, vehicle, n = 4 mice; PLX4720, n = 5 mice. (F) Biochemical analysis of cleaved caspase 3 in protein extract of COLO205 and
SK-MEL-28 xenografts. Protein loading was normalized by vinculin. At least four independent samples were evaluated.
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approaches suggests that antiangiogenic therapy based on in-
hibition of oncogenes in the epithelial compartment has a
greater chance to positively affect the vascular network com-
pared with blockade of the VEGF pathway.
PLX4720 Down-Regulates Expression and Secretion of Proangiogenic
Factors in BRAF Mutant Cancer Cells. To further assess whether the
antiangiogenic effect of PLX4720 was direct (on the tumor
vasculature) or indirect (via epithelial cells), we investigated if
PLX4720 affected ECs in vitro. We found that proliferation and
migration of ECs were unaffected by drug treatment (Fig. S3),
thus ruling out a possible direct effect of BRAF inhibition on the
endothelial compartment. We next considered if PLX4720 was
capable of modulating the production of angiogenic molecules
by cancer cells, which in turn might inﬂuence the tumor envi-
ronment. To assess this, we analyzed the effect of BRAF in-
hibition on the expression of angiogenic factors in colorectal and
melanoma cells carrying mutant BRAF. We found that, upon
PLX4720 treatment, multiple mediators of angiogenesis (e.g.,
CXCL1-2–3, IL-1β, and IL-8 and VEGF-A) were down-regu-
lated in COLO205 and SK-MEL-28. On the contrary, the same
genes were not modulated in the BRAF WT DiFi colorectal
cancer cells (Fig. 6 A and B). Additionally, the effect of PLX4720
on VEGF production was not modiﬁed by hypoxia, an experi-
mental condition that mimics tumors environment (Fig. 6B).
Oncogenic BRAF is a key player in the activation of the MAPK-
ERK signaling cascade. We therefore reasoned that the control
of VEGF expression by PLX4720 might be caused by the in-
hibition of MAPK signaling. Treatment with the MEK inhibitor
AZD6244 decreased VEGF secretion, thus suggesting that
MAPK signaling pathway is essential for VEGF expression (Fig.
6B). ERK has been previously shown to inﬂuence protein
translation through the control of the phosphorylation status of
Fig. 3. PLX4720 treatment stabilizes blood vessels in COLO205 and SK-MEL-
28 xenograft models. (A) Representative images of immunoﬂuorescence
analysis with the CD31 endothelial marker (green) in COLO205 (a–c) and SK-
MEL-28 (d–f) tumors. (Scale bar: 100 μm.) (B) Percentage of surface area
occupied by vessels quantiﬁed by CD31 staining. Bars show mean ± SEM.
(§§P < 0.001 and §P < 0.01, Student t test). For COLO205, start point, n = 8
mice; vehicle, n = 9 mice; PLX4720, n = 14 mice; for SK-MEL-28, start point,
n = 6 mice; vehicle, n = 5 mice; PLX4720, n = 5 mice. (C) Quantiﬁcation of
blood vessel lumen diameter. Red bars represent the median for each group
(§§P < 0.0001, Student t test). Dots indicate the individual vessels measured
for the indicated cell lines. (D) Representative images of colocalization
analysis between perfused beads (red) and CD31 (green) in COLO205. (Scale
bar: 50 μm.) Quantiﬁcation is shown as mean ± SEM of colocalization area
(in μm2; §§P < 0.01 and §P < 0.05, Student t test). COLO205, start point, n = 39
blood vessels; vehicle, n = 30 blood vessels; PLX4720, n = 35 blood vessels.
S.p., start point; V, vehicle; P, PLX4720.
Fig. 4. PLX4720 treatment abolishes tumor hypoxia and decreases necrosis
in COLO205 and SK-MEL-28 xenograft models. Histological analysis of
COLO205 and SK-MEL-28 xenografts before and after PLX4720 treatment.
(A) Representative images of pimonidazole and H&E staining in COLO205
(a–c and d–f) and SK-MEL-28 (g–i and j–l) tumors. (Scale bar: 100 μm.) (B)
Quantiﬁcation of the hypoxic area (percentage) by pimonidazole staining.
Bars show mean ± SEM (§§P < 0.005 and §P < 0.05, Student t test). For
COLO205, start point, n = 7 mice; vehicle, n = 8 mice; PLX4720, n = 8 mice; for
SK-MEL-28, start point, n = 6 mice; vehicle, n = 5 mice; PLX4720, n = 5 mice.
(C) Quantiﬁcation of necrotic area after H&E staining in COLO205 and SK-
MEL-28 xenografts. Bars represent the percentage mean area ± SEM (§§P <
0.01 and §P < 0.05, Student t test). For COLO205, start point, n = 8 mice;
vehicle, n = 9 mice; PLX4720, n = 14 mice; for SK-MEL-28, start point, n = 6
mice; vehicle, n = 5 mice; PLX4720, n = 5 mice.
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p90RSK1, 4EBP1, and eIF4E translation initiating factor. It is
known that activation of ERK induces the phosphorylation of
eIF4E by the MNK kinase (31) and of 4EBP1 by inactivation of
TSC2 through p90RSK (32). In turn, phosphorylation of 4EBP1
releases eIF4E, thus allowing protein translation. We found that
PLX4720 turns off the MAPK pathway in BRAFV600E mutated
cells, resulting in decreased phosphorylation of p90RSK1,
4EBP1, and eIF4E. The same effect could not be recapitulated
in DiFi cancer cells, demonstrating that it is dependent on the
presence of oncogenic BRAF (Fig. 6C). Overall, these results
indicate that BRAFV600E targeted by PLX4720 modiﬁes the
proangiogenic program by acting on the MAPK pathway.
Discussion
To support the exponential growth of solid tumors, new blood
vessels are continuously formed (1, 2). This active process is
mainly sustained by cancer cells that produce and release an-
giogenic factors into the microenvironment, thus promoting
neoangiogenesis. Antiangiogenic therapies have been developed
to target this course of action, which is primarily driven by sol-
uble growth factors such as VEGF (33, 34).
Therapies aimed at interfering with the tumor microenviron-
ment and those that directly target cancer cells are often consid-
ered to represent two independent approaches. This discrepancy
occurs despite the fact that the epithelial and stromal compart-
ments are clearly linked at the structural and functional levels.
How activation of a given oncogene in epithelial cells modulates
the angiogenic response of the surrounding stromal cells is largely
unknown. We and others have shown that the mutational proﬁle of
individual tumors affect their response to targeted therapies (35,
36). For example, EGFR kinase inhibitors are mainly active in lung
cancer cells carrying mutations in the receptor (37, 38); likewise,
the occurrence of KRAS mutations impairs the efﬁcacy of anti-
EGFR monoclonal antibodies in colorectal cancer (39–41). These
ﬁndings are helping clinicians to match patients with appropriate
drugs, a process often referred to as personalized medicine. Clin-
ical evidence indicates that antiangiogenic therapies are also
mainly effective in distinct patient subpopulations, although the
molecular bases for this are still unknown (42–44). It is therefore
tempting to speculate that the genetic milieu of the epithelial
compartment dictates an individual’s response to antiangiogenic
therapies by modulating the tumor microenvironment.
In this work, we explored the possibility that the mutational
activation of an individual oncogene affects the angiogenic po-
tential of cancer cells. As a model, we chose BRAFV600E, one of
the most aggressive oncogenes frequently detected in colorectal
tumors and melanomas (10, 12). We took advantage of a KI
model, in which BRAF mutation has been introduced into the
genome of non-transformed epithelial cells, hence closely re-
capitulating the situation observed in human neoplasms (30). This
strategy overcomes the limitations of previous studies in which
expression of cancer alleles was driven by viral promoters, result-
ing in expression levels many fold greater than in an endogenous
setting. We report that BRAF mutant cells display up-regulation
of proangiogenic factors and actively recruited the endothelium. In
tumor cells, blockage of BRAFV600E with the speciﬁc PLX4720
inhibitor not only exerted a cytostatic activity, but inﬂuenced the
architecture of tumor vasculature. Notably, PLX4720 treatment
did not affect ECs directly; rather, it down-regulated the expres-
sion of angiogenic factors in tumor cells by switching off the
MAPK pathway and p90RSK-dependent translation.
Treatment with PLX4720 strongly inﬂuenced the morphology
of the tumor vasculature in the cellular models (COLO205 and
SK-MEL-28) that were analyzed. Speciﬁcally, the BRAF in-
hibitor modiﬁed the architecture and the functionality of the
vessels, which appeared more regularly shaped, and provided
a better perfusion of the tumor. Furthermore, in both COLO205
and SK-MEL-28, PLX4720 reduced necrosis and almost com-
pletely abrogated tumor hypoxia. We propose that, in addition to
the well established growth inhibitory activities on BRAF mutant
cancer cells, PLX4720 affects tumor growth by stabilizing the vas-
culature and ameliorating tissue perfusion. At least in the experi-
mental conditions we tested, BRAFV600E targeting by PLX4720
showed some advantageous features compared with the classical
anti-angiogenic therapy with bevacizumab. The latter clearly
reduced tumor growth and angiogenesis but did not improve
oxygenation or reduce hypoxia. These results are reminiscent of
data obtained in mouse models of pancreatic neuroendocrine
Fig. 5. Effect of bevacizumab on tumor growth and vasculature. COLO205
xenografts were treated with bevacizumab 10 mg/kg or vehicle for 2 wk
after tumor volume reached an average of 150 to 200 mm3. (A) Tumor
growth curve of COLO205; arrow indicates time point at which treatments
were started. Data are presented as mean tumor volume ± SEM of ﬁve
mice. (B) Representative images of H&E (a and b) and pimonidazole
staining (c and d) in COLO205. (Scale bar: 100 μm.) Colocalization analysis
between perfused beads (red) and CD31 (green) in COLO205 (e–h). (Scale
bar: 50 μm.) (C ) Percentage of surface area occupied by vessels quantiﬁed
by CD31 staining. Bars show mean ± SEM (§§P < 0.01, Student t test). Ve-
hicle, n = 5 mice; bevacizumab, n = 6 mice. (D) Analysis of colocalization
area between perfused beads and CD31. Quantiﬁcation is shown as mean ±
SEM of colocalization area (in μm2; §§P < 0.01). Vehicle, n = 35 blood
vessels; bevacizumab, n = 15 blood vessels. (E ) Quantiﬁcation of the per-
centage hypoxic area by pimonidazole staining. Bars show mean ± SEM.
Start point, n = 4 mice; vehicle, n = 5 mice; bevacizumab, n = 6 mice. (F )
Quantiﬁcation of necrotic area by H&E staining. Bars represent the per-
centage mean area ± SEM. Start point, n = 4 mice; vehicle, n = 5 mice;
bevacizumab, n = 6 mice.
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tumor and glioblastoma, whereby compounds that inhibit VEGF
receptor 2 induce a marked hypoxia (45, 46).
Although the overall effect of BRAF inhibition was consistent
in the two cell types, treatment of SK-MEL-28 reduced the vas-
cularized area whereas the opposite occurred when COLO205
tumors were treated. A number of explanations could account for
this difference. It has been reported that the ratio of the VEGF-
A isoforms dictates the ﬁnal shape of the vasculature and regu-
lates blood ﬂow by inﬂuencing vessel size (47, 48). It is possible
that the VEGF isoforms and other cytokines are modulated to
different extents in the two models. Moreover, VEGF activities
may be ﬁnely tuned by speciﬁc coreceptors of VEGF-receptor 2
(e.g., neuropilins, integrins) that may be differentially expressed
on the capillaries of the two xenografts (49). Finally, the effect of
PLX4720 on SK-MEL-28 tumor vasculature is in line with the
phenotype observed by treating melanoma tumors with VEGF-
receptor inhibitor. As a matter of fact, in the SK-MEL-3 mela-
noma model, treatment with sunitinib caused a signiﬁcantly de-
crease in vessel density, but the pressure of oxygen and uptake of
contrast agent used in resonance imaging were increased (50).
The efﬁcacy and safety of antiangiogenic agents has recently been
questioned based on the discovery that reducing the blood supply to
cancer cells causes hypoxia and could favor metastasization (45, 46,
51). In this regard, our work suggests that the pharmacological in-
hibition of an oncogenic mutation, which causally contributes to the
imbalance between pro- and antiangiogenic mediators, may repre-
sent another valuable strategy to target tumor angiogenesis.
Materials and Methods
Isogenic Cell Model. hTERT-HME1 cells were purchased from American Type
Culture Collection, and KI cells for BRAFV600E were obtained through adenoas-
sociated viral-mediated homologous recombination as previously described (30).
CAM Assay. Fertilized chicken embryos were incubated for 3 d at 37 °C and
70% humidity. A small hole was made over the air sac at the end of the egg,
and a second hole was made directly over the embryonic CAM. After 10 d,
hTERT-HME1 WT or BRAFV600E KI cells were inoculated onto CAM for 48 h. In
detail, 1 × 106 cells were mixed with 50 μL of serum-free DMEM plus 50 μL of
Matrigel (growth factors reduced; Becton-Dickinson) and dropped onto
the CAM to form a plug. CAMs were ﬁxed with PBS solution/3.7% para-
formaldehyde for 10 min at room temperature, and images were taken with
a QIcam FAST1394 digital color camera (QImaging) connected to the ste-
reomicroscope (model SZX9;Olympus). SI Materials and Methods describes
the quantiﬁcation of CAM vasculature.
Mouse Xenografts. All animal procedures were approved by the ethical
commission of the University of Turin and the Italian Ministry of Health.
COLO205 (5 × 106 cells per mouse) or SK-MEL-28 (8 × 106 cells per mouse)
were injected s.c. into the right posterior ﬂanks of 7-wk-old immunodeﬁ-
cient NOD/SCID female mice (6 mice per group; Charles River). Tumor for-
mation was monitored twice per week, and tumor volume based on caliper
measurements was calculated by the modiﬁed ellipsoid formula (i.e., half
the product of length and the square of width). When tumors reached
a volume of approximately 150 to 200 mm3, mice were randomized and
treated by daily gavage for 2 wk with vehicle (1% methylcellulose, 5%
DMSO in sterile water) or PLX4720 60 mg/kg.
Fig. 6. PLX4720 treatment down-regulates the expression of proangiogenic factors. (A) Expression of proangiogenic factors was evaluated by real-time PCR.
Cells carrying BRAFV600E, COLO205, and SK-MEL-28, and BRAF WT DiFi cells were treated for 24 h with PLX4720. Data are expressed as relative quantity (RQ) of
PLX4720 compared with vehicle-treated samples. Bars show mean ± SD of triplicate measurements. (B) Quantiﬁcation of secreted VEGF-A in cells supernatant
by ELISA after 24 h of the indicated treatments. Data are expressed in pg/mL and bars represent mean ± SEM of duplicate observations. The representative of
two experiments is shown. (C) Biochemical analysis of phospho-p90RSK1, -eIF4E, and -4EBP1 in COLO205, SK-MEL-28, and DiFi cells. Protein loading was
normalized by vinculin. Starved cells were stimulated for 30 min with 2.5% FBS plus 1 μM PLX4720 or vehicle.
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Hypoxia Assay. Tumor hypoxia was detected by the formation of pimoni-
dazole adducts with a Hypoxyprobe-1 Plus (FITC-mAb) kit (HP2-200; HPI)
following manufacturer instructions. Details about the procedure and
quantiﬁcation are provided in SI Materials and Methods.
Tumor Vasculature Quantiﬁcation. The following primary antibodies were used
for histological analysis: rabbit anti-von Willebrand Factor (vWF; A0082;
DakoCytomation), mouse anti–HLA-ABC antigen (M0736; DakoCytomation),
rabbit anti-Ki67 (RM-9106-F0; Thermo Scientiﬁc) rat anti-CD31 (Pecam-1;
550274BD; Pharmingen), anti-NG2 (chondroitin sulfate proteoglycan poly-
clonal; AB5320; Chemicon). Quantiﬁcations on tumor vasculature were per-
formed with Image-Pro Plus 6.2 software (Media Cybernetics). The surface
area occupied by vessels was quantiﬁed as surface area of anti-CD31 antibody
staining compared with total tissue area visualized by DAPI. For each animal,
the total vessel area of at least four ﬁeld/images was quantiﬁed.
Quantiﬁcation of blood vessel lumen diameter was performed on single
stack images with Image-Pro Plus 6.2 software (Media Cybernetics). This
analysis was performed with the same images used for determination of
surface area occupied by vessels.
ACKNOWLEDGMENTS. We thank Famarco and Susa Trasporti for providing
white Leghorn chicken eggs; Dr. G. Serini, Dr. Paolo Michieli, Dr. Enrico
Giraudo, Dr. Serena Marchiò, and Dr. Emily Crowley for criticisms and sug-
gestions; and Dr. Sebastjian Hobor and Dr. Sandra Misale for help with
mouse handling and ELISA experiments. Work in the laboratories of the
authors is supported by the Italian Association for Cancer Research
(A. Bardelli and F.B.); the Italian Ministry of Health, Ricerca Oncologica-PIO
2006 (to A. Bardelli); Ricerca Finalizzata 2006 (F.B.); Fondo per gli Investi-
menti della Ricerca di Base Grant RBAP11BYNP (to F.B.); Nanosistemi avan-
zati per una nuova oncologia molecolare (NEWTON) (F.B.); Regione
Piemonte, Ricerca Finalizzata 2008–2009 (A. Bardelli, F.D.N., and F.B.);
Ricerca Industriale e Competitiva 2006; Ricerca Tecnologie Convergenti
2007; Grant Photonic Biosensors for Early Cancer Diagnostics; Piattaforme
Tecnologiche per le Biotecnologie Grant Druidi (Drug Innovation and Dis-
covery); the Italian Ministry of University and Research (A. Bardelli and F.B.).
The research leading to these results has received funding from the Euro-
pean Community’s Seventh Framework Programme under grant agreement
n. 259015 COLTHERES (to A. Bardelli) and grant agreement n. 218071 CAN-
CERGENE (to A. Bardelli); Associazione Italiana per la Ricerca sul Cancro
(AIRC)–2010 Special Program Molecular Clinical Oncology 5xMille, project
9970 (to A. Bardelli and F.B.); Fondazione CRT-Torino (F.B.); and Intramural
Grant “5 × mille” 2008 Fondazione Piemontese per la Ricerca sul Cancro
ONLUS (to A. Bardelli and F.D.N.).
1. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic
switch during tumorigenesis. Cell 86:353–364.
2. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev
Cancer 3:401–410.
3. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in
antiangiogenic therapy. Science 307:58–62.
4. Bottaro DP, Liotta LA (2003) Cancer: Out of air is not out of action. Nature 423:
593–595.
5. Vaupel P, Kelleher DK, Höckel M (2001) Oxygen status ofmalignant tumors: pathogenesis
of hypoxia and signiﬁcance for tumor therapy. Semin Oncol 28(2 suppl 8)29–35.
6. Rak J, Yu JL, Kerbel RS, Coomber BL (2002) What do oncogenic mutations have to do
with angiogenesis/vascular dependence of tumors? Cancer Res 62:1931–1934.
7. Rak J, et al. (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: Implications
for induction and inhibition of tumor angiogenesis. Cancer Res 55:4575–4580.
8. Okada F, et al. (1998) Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-
regulation of vascular endothelial growth factor/vascular permeability factor is
necessary, but not sufﬁcient for tumorigenicity of human colorectal carcinoma cells.
Proc Natl Acad Sci USA 95:3609–3614.
9. Sparmann A, Bar-Sagi D (2004) Ras-induced interleukin-8 expression plays a critical
role in tumor growth and angiogenesis. Cancer Cell 6:447–458.
10. Davies H, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:
949–954.
11. Wan PT, et al.; Cancer Genome Project (2004) Mechanism of activation of the RAF-
ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867.
12. Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. Cancer
Cell 6:313–319.
13. Sartore-Bianchi A, et al. (2009) Multi-determinants analysis of molecular alterations
for predicting clinical beneﬁt to EGFR-targeted monoclonal antibodies in colorectal
cancer. PLoS ONE 4:e7287.
14. Souglakos J, et al. (2009) Prognostic and predictive value of common mutations for
treatment response and survival in patients with metastatic colorectal cancer. Br J
Cancer 101:465–472.
15. Xing M, et al. (2005) BRAF mutation predicts a poorer clinical prognosis for papillary
thyroid cancer. J Clin Endocrinol Metab 90:6373–6379.
16. Xing M (2010) Prognostic utility of BRAF mutation in papillary thyroid cancer.Mol Cell
Endocrinol 321:86–93.
17. Tol J, Nagtegaal ID, Punt CJ (2009) BRAF mutation in metastatic colorectal cancer. N
Engl J Med 361:98–99.
18. SumimotoH, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway
is essential for cancer-immune evasion in humanmelanoma cells. J ExpMed 203:1651–1656.
19. Mesa C, Jr., et al. (2006) Conditional activation of RET/PTC3 and BRAFV600E in thyroid
cells is associated with gene expression proﬁles that predict a preferential role of
BRAF in extracellular matrix remodeling. Cancer Res 66:6521–6529.
20. Kumar SM, et al. (2007) Mutant V600E BRAF increases hypoxia inducible factor-1alpha
expression in melanoma. Cancer Res 67:3177–3184.
21. Zerilli M, et al. (2010) BRAF(V600E) mutation inﬂuences hypoxia-inducible factor-
1alpha expression levels in papillary thyroid cancer. Mod Pathol 23:1052–1060.
22. Kikuchi H, Pino MS, Zeng M, Shirasawa S, Chung DC (2009) Oncogenic KRAS and BRAF
differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer.
Cancer Res 69:8499–8506.
23. Sharma A, et al. (2005) Mutant V599EB-Raf regulates growth and vascular
development of malignant melanoma tumors. Cancer Res 65:2412–2421.
24. Liang S, Sharma A, Peng HH, Robertson G, Dong C (2007) Targeting mutant (V600E) B-
Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma
extravasation. Cancer Res 67:5814–5820.
25. Niault TS, Baccarini M (2010) Targets of Raf in tumorigenesis. Carcinogenesis 31:
1165–1174.
26. Nucera C, et al. (2010) B-Raf(V600E) and thrombospondin-1 promote thyroid cancer
progression. Proc Natl Acad Sci USA 107:10649–10654.
27. Bollag G, et al. (2010) Clinical efﬁcacy of a RAF inhibitor needs broad target blockade
in BRAF-mutant melanoma. Nature 467:596–599.
28. Flaherty KT, et al. (2010) Inhibition of mutated, activated BRAF in metastatic
melanoma. N Engl J Med 363:809–819.
29. Chapman PB, et al.; BRIM-3 Study Group (2011) Improved survival with vemurafenib
in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516.
30. Di Nicolantonio F, et al. (2008) Replacement of normal with mutant alleles in the
genome of normal human cells unveils mutation-speciﬁc drug responses. Proc Natl
Acad Sci USA 105:20864–20869.
31. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R (2004) Mnk2 and
Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic
initiation factor 4E but not for cell growth or development.Mol Cell Biol 24:6539–6549.
32. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004) Tumor-promoting phorbol esters
and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90
ribosomal S6 kinase. Proc Natl Acad Sci USA 101:13489–13494.
33. Ferrara N, Mass RD, Campa C, Kim R (2007) Targeting VEGF-A to treat cancer and age-
related macular degeneration. Annu Rev Med 58:491–504.
34. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967–974.
35. Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and
panitumumab in colorectal cancer. J Clin Oncol 28:1254–1261.
36. Normanno N, et al. (2009) Implications for KRAS status and EGFR-targeted therapies
in metastatic CRC. Nat Rev Clin Oncol 6:519–527.
37. Lynch TJ, et al. (2004) Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to geﬁtinib. N Engl J Med
350:2129–2139.
38. Paez JG, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response
to geﬁtinib therapy. Science 304:1497–1500.
39. Lièvre A, et al. (2006) KRAS mutation status is predictive of response to cetuximab
therapy in colorectal cancer. Cancer Res 66:3992–3995.
40. Benvenuti S, et al. (2007) Oncogenic activation of the RAS/RAF signaling pathway
impairs the response of metastatic colorectal cancers to anti-epidermal growth factor
receptor antibody therapies. Cancer Res 67:2643–2648.
41. Karapetis CS, et al. (2008) K-ras mutations and beneﬁt from cetuximab in advanced
colorectal cancer. N Engl J Med 359:1757–1765.
42. Kabbinavar FF, et al. (2005) Addition of bevacizumab to bolus ﬂuorouracil and
leucovorin in ﬁrst-line metastatic colorectal cancer: Results of a randomized phase II
trial. J Clin Oncol 23:3697–3705.
43. Johnson DH, et al. (2004) Randomized phase II trial comparing bevacizumab plus
carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated
locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184–2191.
44. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab
in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A
Gynecologic Oncology Group Study. J Clin Oncol 25:5165–5171.
45. Pàez-Ribes M, et al. (2009) Antiangiogenic therapy elicits malignant progression of
tumors to increased local invasion and distant metastasis. Cancer Cell 15:220–231.
46. Ebos JM, et al. (2009) Accelerated metastasis after short-term treatment with a potent
inhibitor of tumor angiogenesis. Cancer Cell 15:232–239.
47. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A
by matrix metalloproteinases regulates bioavailability and vascular patterning in
tumors. J Cell Biol 169:681–691.
48. Gerhardt H, et al. (2003) VEGF guides angiogenic sprouting utilizing endothelial tip
cell ﬁlopodia. J Cell Biol 161:1163–1177.
49. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat
Med 9:669–676.
50. Eichhorn ME, et al. (2008) Contrast enhanced MRI and intravital ﬂuorescence
microscopy indicate improved tumor microcirculation in highly vascularized
melanomas upon short-term anti-VEGFR treatment. Cancer Biol Ther 7:1006–1013.
51. Chan DA, Giaccia AJ (2007) Hypoxia, gene expression, and metastasis. Cancer
Metastasis Rev 26:333–339.
Bottos et al. PNAS | February 7, 2012 | vol. 109 | no. 6 | E359
M
ED
IC
A
L
SC
IE
N
CE
S
PN
A
S
PL
U
S
